News

Ophthalmology Times10h
Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for non-proliferative diabetic retinopathy
VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to ...